EXHIBIT 99.1 Exhibit 99.1 Press Release INVESTOR RELATIONS CONTACT: Ralph Giacobbe 860-787-7968 Ralph.Giacobbe@TheCignaGroup.com MEDIA CONTACT: Justine Sessions 860-810-6523 Justine.Sessions@Evernorth.com The Cigna Group Reports Strong Fourth Quarter and Full Year 2025 Results, Establishes 2026 Outlook and Increases Dividend • Total revenues for 2025 increased 11 % to $274.9 billion • Shareholders’ net income for 2025 was $6.0 billion , or $22.18 per share • Adjusted income from operations 1 for 2025 was $8.0 billion , or $29.84 per share • 2026 adjusted income from operations 1 is projected to be at least $7.950 billion, or at least $30.25 per share 2 • Board of Directors declared an increase in the quarterly dividend to $1.56 per share BLOOMFIELD, CT, February 5, 2026 – Global health company The Cigna Group (NYSE: CI) today reported 2025 results, underscoring operational discipline and the strength of its complimentary portfolio of global health businesses. “In 2025, we expanded access and support, lowered costs, and improved transparency for our customers and patients,” said David M. Cordani, chairman and CEO of The Cigna Group. “As we enter the new year, we are well‑positioned to build on this momentum, fueled by our innovations that leverage our diversified businesses and track record of strong financial performance.” Shareholders’ net income for fourth quarter 2025 was $1.2 billion, or $4.64 per share. This compares with $1.4 billion , or $5.13 per share, for fourth quarter 2024 . The Cigna Group’s adjusted income from operations 1 for fourth quarter 2025 was $2.1 billion , or $8.08 per share, compared with $1.8 billion , or $6.64 per share, for fourth quarter 2024. Shareholders’ net income for 2025 was $6.0 billion , or $22.18 per share. This compares with $3.4 billion , or $12.12 per share for 2024 , which included a one-time non-cash after-tax investment loss of $2.7 billion, or $9.53 per share. The Cigna Group’s adjusted income from operations 1 for 2025 was $8.0 billion , or $29.84 per share, compared with $7.7 billion , or $27.33 per share, for 2024 . A reconciliation of shareholders’ net income to adjusted income from operations 1 is provided on the following page and on Exhibit 1 of this earnings release. 2 CONSOLIDATED HIGHLIGHTS The following table includes highlights of results and reconciliations of total revenues to adjusted revenues 3 and shareholders’ net income to adjusted income from operations 1 : Consolidated Financial Results (unaudited, dollars in millions): Three Months Ended December 31, Year Ended December 31, 2025 2024 2025 2024 Total Revenues $ 72,472 $ 65,649 $ 274,900 $ 247,121 Net Investment Results from Equity Method Investments 3 23 34 (249 ) (204 ) Special Item related to Impairment of dividend receivable 3 — — — 182 Adjusted Revenues 3 $ 72,495 $ 65,683 $ 274,651 $ 247,099 Consolidated Earnings, net of taxes Shareholders’ Net Income $ 1,234 $ 1,424 $ 5,957 $ 3,434 Net Investment (Gains) Losses 1 104 (18 ) (90 ) 2,529 Amortization of Acquired Intangible Assets 1 327 375 1,325 1,347 Special Items 1 483 64 822 431 Adjusted Income from Operations 1 $ 2,148 $ 1,845 $ 8,014 $ 7,741 Shareholders’ Net Income, per share $ 4.64 $ 5.13 $ 22.18 $ 12.12 Adjusted Income from Operations 1 , per share $ 8.08 $ 6.64 $ 29.84 $ 27.33 • Total revenues for fourth quarter 2025 and full year 2025 increased 10 % and 11 %, respectively, relative to fourth quarter 2024 and full year 2024 , primarily driven by Evernorth Health Services and includes growth of existing client relationships and strong specialty pharmacy growth. • Adjusted income from operations 1 for fourth quarter 2025 increased 16 % relative to fourth quarter 2024 , driven by higher contributions primarily from Cigna Healthcare, as well as Evernorth Health Services. • Adjusted income from operations 1 for 2025 increased 4 % from 2024, reflecting strong growth in Evernorth Health Services, primarily within Specialty and Care Services. • The SG&A expense ratio 4 and adjusted SG&A expense ratio 4 were 5.0% and 4.7% for fourth quarter 2025 , compared to 5.9% and 5.7% in fourth quarter 2024 , and 5.3 % and 5.0 % for full year 2025 , compared to 6.0 % and 5.9 %, for full year 2024 , reflectin g business mix shift. • The debt-to-capitalization ratio was 43.0% at December 31, 2025, compared to 44.9% at September 30, 2025 and 43.8% at December 31, 2024. • In 2025 , the Company repurchased 11.9 million shares of common stock for approximately $3.6 billion . • On February 5, 2026, the Company’s Board of Directors declared a cash quarterly dividend of $1.56 per share of Cigna common stock to be paid on March 19, 2026 to shareholders of record as of the close of trading on March 5, 2026. This reflects an increase from the 2025 cash quarterly dividend of $1.51 per share. 3 CUSTOMER RELATIONSHIPS The following table summarizes The Cigna Group’s medical customers and overall customer relationships: Customer Relationships (in thousands): As of the Periods Ended December 31, 2025 2024 Total Pharmacy Customers 5 123,603 118,304 U.S. Healthcare 16,423 17,502 International Health 1,695 1,645 Total Medical Customers 5 18,118 19,147 Behavioral Care 28,269 23,932 Dental 18,438 18,258 Medicare Part D — 2,571 Total Customer Relationships 5 188,428 182,212 • Total customer relationships 5 at December 31, 2025 increased 3 % from December 31, 2024 to 188.4 million, reflecting new sales and the continued expansion of relationships in Pharmacy Benefit Services and Behavioral Care, partially offset by the HCSC transaction 6 . • Total pharmacy customers 5 at December 31, 2025 increased 4% from December 31, 2024 to 123.6 million due to new sales and the continued expansion of relationships. • Total medical customers 5 at December 31, 2025 decreased 5% from December 31, 2024 to 18.1 million , primarily reflecting the impact of the HCSC transaction 6 . Excluding the impact of the HCSC transaction 6 , total medical customers 5 as of December 31, 2025 were consistent with December 31, 2024. • Total behavioral customers 5 at December 31, 2025 increased 18 % from December 31, 2024 to 28.3 million due to the onboarding of a new government contract. 4 HIGHLIGHTS OF SEGMENT RESULTS See Exhibit 1 for a reconciliation of adjusted income from operations 1 to shareholders’ net income. Evernorth Health Services This segment includes the Pharmacy Benefit Services and Specialty and Care Services operating segments, which provide independent and coordinated health solutions and capabilities to enable the health care system to work better and help people live healthier lives. Pharmacy Benefit Services drives high-quality, cost-effective pharmacy care through various services such as drug claim adjudication, retail pharmacy network administration, benefit design consultation, drug utilization review, drug formulary management and access to our home delivery pharmacy. Specialty and Care Services provides specialty drugs for the treatment of complex and rare diseases, specialty distribution of pharmaceuticals and medical supplies, as well as clinical programs to help our clients drive better whole-person health outcomes through care services. Financial Results (dollars in millions): Three Months Ended December 31, Year Ended December 31, 2025 2024 2025 2024 Total Adjusted Revenues Pharmacy Benefit Services $ 36,339 $ 30,273 $ 132,126 $ 111,822 Specialty and Care Services $ 26,717 $ 23,471 $ 102,827 $ 90,333 Adjusted Revenues 3 $ 63,056 $ 53,744 $ 234,953 $ 202,155 Adjusted Income from Operations, Pre-Tax Pharmacy Benefit Services $ 1,154 $ 1,198 $ 3,506 $ 3,577 Specialty and Care Services $ 1,034 $ 948 $ 3,715 $ 3,424 Adjusted Income from Operations, Pre-Tax 1 $ 2,188 $ 2,146 $ 7,221 $ 7,001 Margin, Pre-Tax 7 3.5 % 4.0 % 3.1 % 3.5 % • Evernorth Health Services fourth quarter 2025 adjusted revenues 3 and adjusted income from operations, pre-tax 1 , increased 17 % and 2 %, respectively, relative to fourth quarter 2024 . For full year 2025 , adjusted revenues 3 and adjusted income from operations, pre-tax 1 , increased 16 % and 3 %, respectively, relative to 2024 . • For Pharmacy Benefit Services: ◦ Fourth quarter 2025 and full year 2025 adjusted revenues 3 increased 20 % and 18 %, respectively, relative to the fourth quarter 2024 and full year 2024 , reflecting strong organic growth, including the growth of existing client relationships, and new business. ◦ Fourth quarter 2025 and full year 2025 adjusted income from operations, pre-tax 1 , decreased 4 % and 2 %, relative to fourth quarter 2024 and full year 2024 , reflecting strategic investments and initiatives to support business growth and improve the patient experience. • For Specialty and Care Services: ◦ Fourth quarter 2025 and full year 2025 adjusted revenues 3 both increased 14 %, relative to fourth quarter 2024 and full year 2024 , reflecting strong specialty volume growth. ◦ Fourth quarter 2025 and full year 2025 adjusted income from operations, pre-tax 1 , increased 9 % and 8 %, respectively, relative to fourth quarter 2024 and full year 2024 , reflecting strong organic growth in specialty businesses, including increased adoption of biosimilars. 5 Cigna Healthcare This segment includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and customers. U.S. Healthcare provides medical plans and other benefits and solutions for insured and self-insured clients as well as individual and family plan customers . International Health provides health care solutions in our international markets, as well as health solutions for globally mobile individuals and employees of multinational organizations. U.S. Healthcare included the Medicare and related businesses until the divestiture of such businesses to Health Care Services Corporation (“HCSC”) 6 on March 19, 2025. Financial Results (dollars in millions): Three Months Ended December 31, Year Ended December 31, 2025 2024 2025 2024 Adjusted Revenues 3,8 $ 11,172 $ 13,331 $ 47,163 $ 52,914 Adjusted Income from Operations, Pre-Tax 1 $ 734 $ 511 $ 4,153 $ 4,229 Margin, Pre-Tax 7 6.6 % 3.8 % 8.8 % 8.0 % • Fourth quarter 2025 and full year 2025 adjusted revenues 3,8 decreased 16% and 11% , respectively, relative to fourth quarter 2024 and full year 2024 , primarily reflecting the impact of the HCSC transaction 6,8 . Excluding the impact of the HCSC transaction 6,8 , fourth quarter 2025 and full year 2025 adjusted revenues 3,8 increased 8% and 7%, respectively, relative to fourth quarter 2024 and full year 2024 , primarily driven by premium rate increases to cover expected increases in medical costs. • Fourth quarter 2025 adjusted income from operations, pre-tax 1 , increased 44 % relative to fourth quarter 2024 , primarily driven by higher contributions from stop loss products relative to the prior year . Full year 2025 adjusted income from operations, pre-tax 1 , decreased 2% relative to full year 2024 , primarily due to lower contributions from the Individual and Family Plans business. • The Cigna Healthcare MCR 4 was 88.0% for fourth quarter 2025 , compared to 87.9% for fourth quarter 2024 . The Cigna Healthcare MCR 4 was 84.4% for full year 2025 , compared to 83.2% for full year 2024 , primarily due to higher medical costs, driven by the Individual and Family Plans business. • Cigna Healthcare net medical costs payable 9 was $ 4.09 billion at December 31, 2025 , $4.53 billion at September 30, 2025 , and $4.86 billion at December 31, 2024 . The sequential decrease was consistent with prior years, reflecting stop loss seasonality. The year-over-year decrease was primarily driven by the HCSC transaction 6 which included $978 million in net medical costs payable 9 at December 31, 2024 . Favorable prior year reserve development on a gross pre-tax basis was $342 million and $456 million for 2025 and 2024 , respectively. 6 Corporate and Other Operations Corporate reflects interest expense, amounts not allocated to operating segments and includes intersegment eliminations. Other Operations is comprised of Corporate Owned Life Insurance (“COLI”), the Company’s run-off operations and other non-strategic businesses. Financial Results (dollars in millions): Three Months Ended December 31, Year Ended December 31, 2025 2024 2025 2024 3 Adjusted (Loss) from Operations, Pre-Tax 1 $ (373 ) $ (424 ) $ (1,504 ) $ (1,697 ) 7 2026 OUTLOOK 2 The Cigna Group’s outlook 2 for full year 2026 adjusted revenues 2,3 is approximately $280.0 billion. The Cigna Group’s outlook for full year 2026 consolidated adjusted income from operations 1,2 is at least $7.950 billion, or at least $30.25 per share 2 . Additionally, this outlook includes the impact of expected future share repurchases and anticipated 2026 dividends. (dollars in millions, except where noted and per share amounts) 2026 Consolidated Metrics Projection for Full Year Ending December 31, 2026 Adjusted Revenues 2,3 ~$280,000 Adjusted Income from Operations 1,2 at least $7,950 Adjusted Income from Operations, per share 1,2 at least $30.25 Adjusted SG&A Expense Ratio 2,4 ~5.0% Adjusted Effective Tax Rate 2,10 ~19.0% Cash Flow from Operations 2 ~$9,000 Capital Expenditures 2 ~$1,300 Shareholder Dividends 2 ~$1,600 Weighted Average Shares Outstanding (millions) 2 261 to 265 2026 Evernorth Metrics Evernorth Adjusted Income from Operations, Pre-Tax 1,2 at least $6,900 2026 Cigna Healthcare Metrics Cigna Healthcare Adjusted Income from Operations, Pre-Tax 1,2 at least $4,500 Cigna Healthcare Medical Care Ratio 2,4 83.7% to 84.7% Total Medical Customers 2,5 ~18.1M 8 The foregoing statements represent the Company’s current estimates of The Cigna Group’s 2026 consolidated and segment adjusted income from operations 1,2 and other key metrics as of the date of this release. Actual results may differ materially depending on a number of factors. Investors are urged to read the Cautionary Note Regarding Forward-Looking Statements included in this release. Management does not assume any obligation to update these estimates. This quarterly earnings release and the Quarterly Financial Supplement are available on The Cigna Group’s website in the Investor Relations section ( https://investors.thecignagroup.com/overview/default.aspx ). Management will be hosting a conference call to review full year 2025 results and discuss full year 2026 outlook beginning today at 8:30 a.m. ET. A link to the conference call is available in the Investor Relations section of The Cigna Group’s website located at https://investors.thecignagroup.com/events-and-presentations/default.aspx . The call-in numbers for the conference call are as follows: Live Call (888) 566-1889 (Domestic) (773) 799-3989 (International) Passcode: 02052026 Replay (866) 405-7290 (Domestic) (203) 369-0603 (International) It is strongly suggested you dial in to the conference call by 8:15 a.m. ET. About The Cigna Group The Cigna Group (NYSE: CI) is a global health company committed to creating a better future built on the vitality of every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. The Cigna Group includes products and services marketed under Evernorth Health Services, Cigna Healthcare, or its subsidiaries. The Cigna Group maintains sales capabilities in more than 30 markets and jurisdictions, and has more than 185 million customer relationships around the world. Learn more at thecignagroup.com . Notes: 1. Adjusted income (loss) from operations is a principal financial measure of profitability used by The Cigna Group’s management because it presents the underlying results of operations of the Company’s businesses and facilitates analysis of trends in underlying revenue, expenses and shareholders’ net income. Adjusted income (loss) from operations is defined as shareholders’ net income (or income before income taxes less pre-tax income (loss) attributable to noncontrolling interests for the segment metric) excluding net investment gains/losses, amortization of acquired intangible assets and special items. The Cigna Group’s share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. Consolidated adjusted income (loss) from operations is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, shareholders’ net income. See Exhibit 1 for a reconciliation of consolidated adjusted income from operations to shareholders’ net income. 9 2. Management is not able to provide a reconciliation of adjusted income from operations to shareholders’ net income, on a forward-looking basis because it is unable to predict, without unreasonable effort, certain components thereof including (i) future net investment results and (ii) future special items. These items are inherently uncertain and depend on various factors, many of which are beyond The Cigna Group’s control. As such, any associated estimate and its impact on shareholders’ net income and total revenues could vary materially. The Company’s outlook excludes the potential effects of any other business combinations that may occur after the date of this earnings release. The Company’s outlook includes the potential effects of expected future share repurchases and anticipated 2026 dividends. The timing and actual number of shares repurchased will depend on a variety of factors, including price, general business and market conditions, and alternate uses of capital. The share repurchase program may be effected through open market purchases in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended, including through Rule 10b5-1 trading plans, or privately negotiated transactions. The program may be suspended or discontinued at any time. 3. Adjusted revenues is used by The Cigna Group’s management because it facilitates analysis of trends in underlying revenue. The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and The Cigna Group’s share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. We exclude these items from this measure because management believes they are not indicative of past or future underlying performance of the business. Adjusted revenues is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, total revenues. See Exhibit 1 for a reconciliation of consolidated adjusted revenues to total revenues. 4. Operating ratios are defined as follows: • The Cigna Healthcare medical care ratio (“MCR”) represents medical costs as a percentage of premiums for all Cigna Healthcare risk products provided through guaranteed cost or experience-rated funding arrangements. Changes in percentages may be expressed in basis points (“bps”). • SG&A expense ratio on a GAAP basis for the fourth quarter 2025 represents enterprise selling, general and administrative expenses of $3,609 million as a percentage of total revenue of $72.5 billion at a consolidated level. SG&A expense ratio on a GAAP basis for the fourth quarter 2024 represents enterprise selling, general and administrative expenses of $3,865 million as a percentage of total revenue of $65.6 billion at a consolidated level. • SG&A expense ratio on a GAAP basis for the full year 2025 represents enterprise selling, general and administrative expenses of $14,617 million as a percentage of total revenue of $274.9 billion at a consolidated level. SG&A expense ratio on a GAAP basis for the full year 2024 represents enterprise selling, general and administrative expenses of $14,844 million as a percentage of total revenue of $247.1 billion at a consolidated level. 10 • Adjusted SG&A expense ratio for the fourth quarter 2025 represents enterprise selling, general and administrative expenses of $3,430 million excluding special items of $ 179 million as a percentage of adjusted revenue at a consolidated level. Adjusted SG&A expense ratio for the fourth quarter 2024 represents enterprise selling, general and administrative expenses of $3,767 million excluding special items of $ 98 million as a percentage of adjusted revenue at a consolidated lev el. • Adjusted SG&A expense ratio for the full year 2025 represents enterprise selling, general and administrative expenses of $13,691 million excluding special items of $926 million as a percentage of adjusted revenue at a consolidated level. Adjusted SG&A expense ratio for the full year 2024 represents enterprise selling, general and administrative expenses of $14,569 million excluding special items of $275 million as a percentage of adjusted revenue at a consolidated level. 5. Customer relationships are defined as follows: • Total medical customers includes individuals who meet any one of the following criteria: (i) are covered under a medical insurance policy, managed care arrangement, or administrative services agreement issued by Cigna Healthcare; (ii) have access to Cigna Healthcare’s provider network for covered services under their medical plan; or (iii) have medical claims that are administered by Cigna Healthcare. • Total customer relationships and total medical customers as of December 31, 2024, excluding the impact of the HCSC transaction 6 , were 179,712 thousand and 18,055 thousand, respectively. 6. On March 19, 2025, the company completed the sale (the “HCSC transaction”) of its Medicare Advantage, Medicare Individual Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits, and CareAllies businesses to Health Care Services Corporation (“HCSC”). 7. Margin, pre-tax, is calculated by dividing adjusted income (loss) from operations, pre-tax by adjusted revenues for each segment. 8. The Cigna Group owns noncontrolling interests in certain operating joint ventures. As such, the adjusted revenues for the Cigna Healthcare segment only include the Company’s share of the joint ventures’ earnings reported in Fees and Other Revenues using the equity method of accounting under GAAP. Set forth below is a table that presents the impact of the HCSC transaction on Cigna Healthcare Adjusted Revenues for the periods presented. Management believes that the presentation of this measure is useful to investors because it permits a comparison of the Company’s go-forward business across periods. Financial Results (dollars in millions): Three Months Ended December 31, Year Ended December 31, 2025 2024 2025 2024 Cigna Healthcare Adjusted Revenues 3 $ 11,172 $ 13,331 $ 47,163 $ 52,914 Less: U.S. Healthcare - divested businesses revenues — 2,973 3,850 12,348 Cigna Healthcare Adjusted Revenues 3 excluding U.S. Healthcare - divested businesses revenues $ 11,172 $ 10,358 $ 43,313 $ 40,566 11 9. Medical costs payable within the Cigna Healthcare segment are presented net of reinsurance and other recoverables. The gross medical costs payable balance was $4.24 billion as of December 31, 2025 , $4.68 billion as of September 30, 2025 , and $5.02 billion as of December 31, 2024 . 10. The measure “adjusted effective tax rate” is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, “consolidated effective tax rate”. We define adjusted effective tax rate as the consolidated income tax rate applicable to the Company’s pre-tax income excluding pre-tax income (loss) attributable to noncontrolling interests, net investment results, amortization of acquired intangible assets, and special items. The Cigna Group’s share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Management is not able to provide a reconciliation to the consolidated effective tax rate on a forward-looking basis because we are unable to predict, without unreasonable effort, certain components thereof including (i) future net investment results and (ii) future special items. 12 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This press release, and oral statements made in connection with this release, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on The Cigna Group’s current expectations and projections about future trends, events and uncertainties. These statements are not historical facts. Forward-looking statements may include, among others, statements concerning our projected outlook for 2026 (including adjusted revenues; adjusted income from operations, including on a per share, and segment basis; adjusted SG&A expense ratio; adjusted effective tax rate; cash flow from operations; capital expenditures; shareholder dividends; weighted average shares outstanding; medical care ratio; and total medical customers); future financial or operating performance, including our ability to improve the health and vitality of those we serve; future growth, business strategy and strategic or operational initiatives, including our ability to successfully implement actions across our business to strengthen our platform and build a more sustainable model for healthcare; economic, regulatory or competitive environments; capital deployment plans and amounts available for future deployment; our prospects for growth in the coming years; and other statements regarding The Cigna Group’s future beliefs, expectations, plans, intentions, liquidity, cash flows, financial condition or performance. You may identify forward-looking statements by the use of words such as “believe,” “expect,” “project,” “plan,” “intend,” “anticipate,” “estimate,” “predict,” “potential,” “may,” “should,” “will” or other words or expressions of similar meaning, although not all forward-looking statements contain such terms. Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those expressed or implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: our ability to manage healthcare costs and respond to price competition, inflation and other pressures that could compress our margins or result in premiums that are insufficient to cover the cost of services delivered to our customers; our ability to compete effectively, differentiate our products and services from those of our competitors and adapt to changes in an evolving and rapidly changing industry; changes in drug pricing or industry pricing benchmarks; our ability to efficiently transition to a new rebate-free pricing model; our ability to maintain relationships with one or more key pharmaceutical manufacturers or if payments made or discounts provided decline; changes in the pharmacy provider marketplace or pharmacy networks; the potential for actual claims to exceed our estimates related to expected medical claims; our ability to develop and maintain satisfactory relationships with health care payors, physicians, hospitals, other health service providers and with producers and consultants; potential liability in connection with managing medical practices and operating pharmacies, onsite clinics and other types of medical facilities; uncertainties surrounding participation in government-sponsored programs and providing services to payors who participate in government-sponsored programs; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; compliance with applicable privacy, security and data laws, regulations and standards; the outcome of litigation, regulatory audits and investigations; compliance costs and potential failure of our prevention, detection and control systems; our ability to invest in and properly maintain our information technology and other business systems; our ability to prevent or contain effects of a potential cyberattack or other privacy or data security incident; risks related to our use of artificial intelligence and machine learning; dependence on success of relationships with third parties; risk of significant disruption within our operations or among key suppliers or third parties; political, legal, operational, regulatory, economic and other risks that could affect our multinational operations, including currency exchange rates; risks related to strategic transactions and realization of the expected benefits of such transactions, as well as integration or separation difficulties or underperformance relative to expectations which could lead to an impairment charge; our ability to achieve our strategic and operational initiatives; unfavorable economic and market conditions, the risk of a recession or other economic downturn and resulting impact on employment metrics, stock market or changes in interest rates; risks related to a downgrade in financial strength ratings of our insurance subsidiaries; the impact of our significant indebtedness and the potential for further indebtedness in the future; credit risk related to our reinsurers; as well as more specific risks and uncertainties discussed in our most recent report on Form 10-K and subsequent reports on Forms 10-Q and 8-K available through the Investor Relations section of www.thecignagroup.com. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made, are not guarantees of future performance or results, and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. The Cigna Group undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by law. 13 THE CIGNA GROUP Exhibit 1 COMPARATIVE SUMMARY OF FINANCIAL RESULTS (unaudited) Three Months Ended December 31, Year Ended December 31, (Dollars in millions, except per share amounts) 2025 2024 2025 2024 REVENUES Pharmacy revenues $ 58,336 $ 49,941 $ 216,672 $ 185,362 Premiums 9,288 11,503 40,261 45,996 Fees and other revenues 4,509 3,928 16,921 14,790 Net investment income 339 277 1,046 973 Total revenues 72,472 65,649 274,900 247,121 Net investment results from certain equity method investments 23 34 (249 ) (204 ) Special item related to impairment of dividend receivable — — — 182 Adjusted revenues (1) $ 72,495 $ 65,683 $ 274,651 $ 247,099 Shareholders’ net income $ 1,234 $ 1,424 $ 5,957 $ 3,434 Pre-tax adjusted income (loss) from operations by segment Evernorth Health Services $ 2,188 $ 2,146 $ 7,221 $ 7,001 Cigna Healthcare 734 511 4,153 4,229 Corporate and Other Operations (373 ) (424 ) (1,504 ) (1,697 ) Adjusted income tax expense (401 ) (388 ) (1,856 ) (1,792 ) Consolidated after-tax adjusted income from operations $ 2,148 $ 1,845 $ 8,014 $ 7,741 Weighted average shares (in thousands) 265,699 277,784 268,563 283,218 Common shares outstanding (in thousands) 263,464 273,789 SHAREHOLDERS’ EQUITY at December 31, $ 41,713 $ 41,033 SHAREHOLDERS’ EQUITY PER SHARE at December 31, $ 158.33 $ 149.87 Three Months Ended December 31, Year Ended December 31, 2025 2024 2025 2024 (Dollars in millions, except per share amounts) Pre-tax After-tax Pre-tax After-tax Pre-tax After-tax Pre-tax After-tax SHAREHOLDERS’ NET INCOME Shareholders’ net income $ 1,234 $ 1,424 $ 5,957 $ 3,434 Adjustments to reconcile adjusted income from operations Net investment losses (gains) (2) $ 123 104 $ (34 ) (18 ) $ (225 ) (90 ) $ 2,533 2,529 Amortization of acquired intangible assets 463 327 424 375 1,743 1,325 1,703 1,347 Special Items Deferred tax expenses, net — 374 — 9 — 427 — 84 Strategic optimization program 183 136 — — 749 565 — — Integration and transaction-related costs 30 21 98 76 327 247 275 211 Net loss (gain) on sale of businesses 66 (48 ) (130 ) (21 ) (13 ) (404 ) (24 ) (2 ) Benefits associated with litigation matters — — — — (17 ) (13 ) — — Impairment of dividend receivable — — — — — — 182 138 Adjusted income from operations (3) $ 2,148 $ 1,845 $ 8,014 $ 7,741 DILUTED EARNINGS PER SHARE Shareholders’ net income $ 4.64 $ 5.13 $ 22.18 $ 12.12 Adjustments to reconcile to adjusted income from operations Net investment losses (gains) (2) $ 0.46 0.39 $ (0.12 ) (0.06 ) $ (0.84 ) (0.34 ) $ 8.95 8.93 Amortization of acquired intangible assets 1.74 1.23 1.53 1.34 6.50 4.94 6.01 4.76 Special Items Deferred tax expenses, net — 1.41 — 0.03 — 1.59 — 0.30 Strategic optimization program 0.69 0.51 — — 2.78 2.10 — — Integration and transaction-related costs 0.11 0.08 0.35 0.27 1.22 0.92 0.97 0.75 Net loss (gain) on sale of businesses 0.25 (0.18 ) (0.47 ) (0.07 ) (0.05 ) (1.50 ) (0.08 ) (0.02 ) Benefits associated with litigation matters — — — — (0.06 ) (0.05 ) — — Impairment of dividend receivable — — — — — — 0.64 0.49 Adjusted income from operations (3) $ 8.08 $ 6.64 $ 29.84 $ 27.33 (1) Adjusted revenues is defined as total revenues excluding the following adjustments: special items and The Cigna Group’s share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. These items are excluded because they are not indicative of past or future underlying performance of our businesses. (2) Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company’s share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income. (3) Adjusted income (loss) from operations is defined as shareholders’ net income (or income before income taxes less pre-tax income (loss) attributable to noncontrolling interests for the segment metric) excluding the following adjustments: net investment gains/losses, amortization of acquired intangible assets and special items. The Cigna Group’s share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded.

the item shown at left

other guidance in this release

Text is the filed exhibit, verbatim.